Sensitization of cancer stem cells to TRAIL has only previously been demonstrated in haematological cancers, including AML [55] and T-cell lymphoma cells [57], both of which have implicated, but not functionally proven, a role for c-FLIP in the process. This evidence concerns the gene CFLAR and T-cell non-Hodgkin lymphoma.